Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Developmental toxicity / teratogenicity

Currently viewing:

Administrative data

developmental toxicity
Type of information:
migrated information: read-across based on grouping of substances (category approach)
Adequacy of study:
weight of evidence
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Comparable to guideline study with acceptable restrictions. Parenteral route of application, only two dose levels, number of corpora lutea not reported.

Data source

Reference Type:

Materials and methods

Test guideline
equivalent or similar to guideline
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
parenteral route of application, only two dose levels, number of corpora lutea not reported
GLP compliance:
not specified
Limit test:

Test material

Constituent 1
Reference substance name:
Medium Chain Triglycerides (MCT)
Medium Chain Triglycerides (MCT)

Test animals

other: Hra:(NZW)SPF rabbits
Details on test animals or test system and environmental conditions:
- Source: HRP, Inc., Denver, PA, USA
- Age at study initiation: 5.5 - 6.5 months
- Weight at study initiation: 3300 - 4446 g
- Housing: individually housed in suspended stainless steel cages
- Diet: certified rabbit diet 5322 (PMI Feeds. Inc.), ad libitum; except during dose administration
- Water: ad libitum; except during dose administration

Environmental controls in the animal rooms were set to maintain temperature, relative humidity, and light/dark cycle (no further information)

Administration / exposure

Route of administration:
other: 20% lipid emulsion, no further specified
Details on exposure:
The dose was administered daily to rabbits via a marginal ear vein using an indwelling catheter [Insyte-W (24-gauge, 3/4-inch intravenous catheter and needle unit attached to a 30-inch extension set, Abbott Laboratories)]. Doses for rabbits were delivered using syringe pumps. The rabbits were acclimated to the dose restraint apparatus for 2.5 and 5 h on the 2 days preceding initiation of dosing.

Analytical verification of doses or concentrations:
not specified
Details on mating procedure:
- Impregnation procedure: purchased timed pregnant
- Mated rabbits were received on gestation day 2 or 3 in two consecutive weekly shipments and were observed at arrival for abnormalities indicative of health problems.
Duration of treatment / exposure:
(P): 13 days during gestation
Frequency of treatment:
5 h/day, 7 days/week
Duration of test:
Day 29 of gestation / post mating
Doses / concentrations
Doses / Concentrations:
1000 and 4280 mg/kg bw/day
nominal conc.
No. of animals per sex per dose:
Control animals:
other: 0.9% saline
Details on study design:
- Dose selection rationale: The dose rate was based on previous preclinical studies (unpublished). The 1000 mg/kg dose approximates the proposed clinical dosage. The 4280 mg/kg dose is the highest dose administered in preclinical studies that did not produce narcosis (unpublished).

- Selection of exposurre route: The intravenous route of administration was used because the lipid emulsion is intended for intravenous human administration as a component of parenteral nutrition.

- Dose volumes: 5 and 21.4 mL/kg


Maternal examinations:
- Time schedule: Animals were observed twice daily (AM and PM) for mortality and moribundity. In addition, rabbits were observed once daily for clinical observations. On dosing days, animals were observed predose, immediately (within 5 min) postdose, and approximately 1 h after completion of dosing.

- Time schedule for examinations: daily and on GD 7 through 29

- Time schedule for examinations: Feed consumption data were collected daily beginning on GD 6.

- Sacrifice on gestation day 29

Ovaries and uterine content:
The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
Fetal examinations:
- External examinations: Yes: all. Live fetuses were weighed, examined externally, then euthanatized.
- Soft tissue examinations: Yes: all. The internal organs of the rabbit fetuses were examined in the fresh state for variations and malformations, and the sex was determined. Following completion of fetal examinations, soft tissue malformations were preserved in 10% phosphate-buffered formalin.
- Skeletal examinations: Yes: all. Viscera were removed and discarded, and fetuses were processed and examined for skeletal variations and malformations; skeletal specimens were retained in glycerine.
- Head examinations: Yes: all. A mid-corona slice of the head was made to expose the internal structure of the brain for examination; the eyes were excised and examined.
The litter was the experimental unit for evaluation. All comparisons were made with the control group (Group 1). For rabbit data, Levene's test (Levene, 1960) was done to test for variance homogeneity. In the case of heterogeneity of variance at p « 0.05, rank transformation was used to stabilize the variance. Analysis of variance [ANOVA (Winer, 1971a)] was done on the homogeneous or transformed data. If the ANOVA was significant, Dunnett's t test (Dunnett, 1964) was used for pairwise comparisons between groups. One-way ANOVA was used to analyse body weights, body weight changes, feed consumption, and cesarcan section data. As appropriate, rabbit fetal abnormality data were analysed by the Cochran-Armitage test (Thalcur et al, 1985) for trend and departure and by the Fisher-Irwin exact test (Thalcur et al., 1985). One-way analysis of covariance [ANCOVA (Winer, 1971b)] was used to analyse fetal body weights (males, females, and combined) with the number of fetuses in the litter as the covariate. As appropriate, for values calculated to analyse litter data or mean fetal weight data, values were first derived within the litter, and the group mean values were derived as a mean of individual litter values. Group comparisons were analysed at the 5.0 and 1.0% two-tailed probability levels.
Early and late resorptions, % fetuses dead/live, % postimplantation loss

Results and discussion

Results: maternal animals

Maternal developmental toxicity

Details on maternal toxic effects:
Maternal toxic effects:yes. Remark: at the highest dose group

Details on maternal toxic effects:
Survival was 100% for the 1000 mg lipid/kg group. One animal in the control group died on GD 11 and one animal given 4280 mg lipid/kg was sacrificed after aborting on GD 20. The animal that aborted had the lowest food consumption in the group. Decreased food consumption, resulting in a decline in the health of this animal, may have contributed to the abortion. The abortion was not considered to be test article-related as it was in the range of historical control incidence. There were no remarkable necropsy findings for either animal. Clinical observations in the test article-treated groups were limited to faecal findings (i.e., increased incidence of few or no faeces). Three animals each at 4280 mg lipid/kg had no faecal output for 1 day during the dosing period.
The data on maternal body weight changes as taken from the tabellary reporting showed a significant loss of body weights during gestational day 7 - 20 in maternal rabbits accompanied by reduced food consumption in the high dose group.
The body weight gain during GD 7-20 was found to be 95.4 g in control animals and 119.6 g in animals dosed with 1000 mg/kg bw/day, whereas at the same time animals dosed with 4280 mg/kg bw/day showed a significant loss of body weight of - 124.8 g (p < 0.01).
Food consumption in the highest dose group was only 50% of the control during GD 12 - 13 and only 10% of the control during GD19 - 20. Food consumption continued to be significantly lower for the highest dose group during the early post-treatment period (GD 20 to 24), but recovery was noted at a later interval (GD 24 to 29). The decreased food consumption observed in this study was an expected occurrence based on the high-caloric nature of the test article. There were no test article-related findings at necropsy. All pregnant animals had at least one viable foetus at scheduled caesarean section on GD 29 (i.e., no dams had total resorptions).

Effect levels (maternal animals)

Key result
Dose descriptor:
maternal toxicity
Effect level:
1 000 mg/kg bw/day
Based on:
test mat.
(i.v. application)
Basis for effect level:
other: strongly reduced food consumption, significant loss of body weight, no faecal output in some animals.

Results (fetuses)

Details on embryotoxic / teratogenic effects:
Embryotoxic / teratogenic effects:yes. Remark: at the highest dose group

Details on embryotoxic / teratogenic effects:
The mean percentage of total resorptions/litter (postimplantation loss) was significantly higher and the mean percentage of live foetuses/litter was correspondingly lower in the 4280 mg lipid/kg group. Mean covariate-adjusted foetal body weights (males, females, and combined) for the 4280 mg lipid/kg group were significantly lower.
The proportion of foetuses and litters in the 4280 mg lipid/kg group with external morphological abnormalities was significantly higher than that of the control group.
The most notable findings were rachischisis and short tail seen in three and two high-dose litters, respectively. Single incidences of the following malformations were also present in the high-dose group: exencephaly, ablepharia, exophthalmus, and ectrodactyly. Single litter incidences of carpal flexure, tarsal flexure, and malpositioned shoulders were noted for the 1000 mg lipid/kg group; however, these were not considered to be test article-related. No external abnormalities were noted for the control group.
The total incidence of litters in the 1000 mg lipid/kg group with foetuses having soft tissue abnormalities was significantly higher than that of the control group; however, no significant differences were present when individual malformations and variations were analysed statistically. Although the incidence of litters in the 4280 mg lipid/kg group with viscerally abnormal foetuses was also higher than controls, the difference was not statistically significant. In general, soft tissue abnormalities were present in the test article-treated groups as single foetal or litter incidences restricted to three or four litters/group, suggesting a litter-related occurrence.
Because no soft tissue abnormalities (with the exception of absent azygous lobe of the lung) were noted for the control litters, the relationship of the abnormalities in the test article groups to the test article is inconclusive.
The proportions of foetuses with variations in the 4280 mg lipid/kg group [skull bones unossified, more than 26 presacral vertebrae, and 12 full pairs of ribs (litter incidence was also greater)] and total skeletal abnormalities were significantly higher than those in the control group. The proportions of litters in this group with foetuses having misaligned sternebrae, more than 12 full pairs of ribs, and fused ribs were also significantly higher than those in the control group.
Though not statistically significant, there was a notable increase in the number of high-dose foetuses/litter with malformations of the vertebral column. The anomalies were varied in location (cervical, thoracic, sacral, and caudal) and type (malformed, misaligned, absent, and fused). The incidence of any one of these findings was not markedly higher than that of the controls (usually only one litter was affected with a given abnormality); however, when combined, the incidence of foetuses/litters from the high-dose group with vertebral column malformations was notably higher than that of the control group.

Effect levels (fetuses)

open allclose all
Key result
Dose descriptor:
developmental toxicity
Effect level:
1 000 mg/kg bw/day
Based on:
test mat.
(i.v. application)
Basis for effect level:
other: See remarks
Key result
Dose descriptor:
Effect level:
4 280 mg/kg bw/day
Based on:
test mat.
(i.v. application)
Basis for effect level:
other: Increased resorptions, decreased foetal body weights, and increased incidence of morphological anomalies at 4280 mg/kg bw/day.

Fetal abnormalities

not specified

Overall developmental toxicity

Developmental effects observed:
not specified

Any other information on results incl. tables

Cesarean section examinations of rabbits revealed higher postimplantation loss (i.e., increased incidence of resorptions) and, correspondingly, fewer live foetuses at the 4280 mg lipid/kg level. Mean foetal weights were lower for this group as well, and more litters in the group tended to have foetuses with morphological anomalies than were seen in the control group. Reduced foetal weights may have been secondary to the decreased maternal food consumption observed at this dose level.

Because treated females were consuming significantly less food than control females, the foetal effects noted for rabbits (especially the postimplantation loss and decreased foetal weights) may have been due to dietary deprivation, as opposed to a direct effect by the test article. Increased incidence of abortion and implant resorption among pregnant rabbits subjected to dietary deprivation have been reported (Matsazawa et at, 1980). There were no related patterns of major malformations for foetuses. Skeletal variations were present in all litters, including control and treated groups. Diverse abnormalities were seen that may have been associated with maternal toxicity (Khera, 1984; Manson, 1986).

Administration of the test article to rabbits at 1000 or 4280 mg lipid/kg resulted in a NOEL for developmental toxicity greater than or equal to 1000 mg lipid/kg but less than 4280 mg lipid/kg based on the adverse foetal findings (increased postimplantation loss, lower foetal body weights, and higher incidence of morphological anomalies) seen at the 4280 mg lipid/kg level. Administration of the test article at the highest dose also resulted in lower maternal food consumption and loss of body weight, therefore the observed foetal effects were probably the result of dietary deprivation, maternal toxicity or both, rather than a direct teratogenic effect of the test article.

Applicant's summary and conclusion